80%Confidence
0Views
FDASource
2026-04-04Date
Summary
Harbin Jixianglong's Semaglutide recall due to validation failures highlights significant regulatory risks in the compounding pharmacy supply chain. This could accelerate FDA scrutiny on compounded weight loss drugs and create supply constraints.
Actionable: Immediately discontinue use of affected Semaglutide lots and source from FDA-approved manufacturers only.
AI Confidence: 80%
Data Points
firmHarbin Jixianglong Biotech Co., Ltd.
classificationClass II
statusOngoing
distributionNationwide within the United States
productSemaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-1
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now